BIOA · BioAge Labs, Inc.
$9.69
-1.06 (-9.86%)
At close · Aug 20
Market Cap
$444.74M
Shares
45.90M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.69
Open$10.64
Day$9.63–10.73
52W close$4.44–25.10
Avg vol 30d1.1M
Short int2.6M · 5.6% float · 1.9d
Short vol66%
Last earningsAug 5, 2026
DataSep 2024–Aug 2026
Filing10-Q · Aug 5
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−42%
below
Price vs 50-day avg
−48%
below
RSI (14)
30
neutral
MACD trend
Negative
52-week position
25%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−56%
trailing
6-month return
−56%
trailing
YTD return
−27%
this year
Relative strength
−68%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $19 › 200d $17 — 50d above 200d
Institutional flow
Accumulating
+3% holders QoQ · +27 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.59% of float · ▲ +4.7% MoM · 1.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
150 holders — near 2-yr high, broad support
Squeeze score
46
elevated · 0–100
Fundamentals
EPS growth
+66%
Y/Y
Free cash flow
$-82.3M
Balance sheet
$186.2M
net cash
Quant / Vol
risk profile
Volatility
109%
annualized · 1-yr
Max drawdown
−64%
past year
ATR
14.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−42%
Bearish
Price vs 50-day avg
−48%
Bearish
RSI (14)
30
Neutral
MACD trend
Negative
Bearish
52-week position
25%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $19 › 200d $17 — 50d above 200d
Institutional flow
Accumulating
+3% holders QoQ · +27 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.59% of float · ▲ +4.7% MoM · 1.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
150 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $4
Now $10 · 25%
Range high $25
vs 200-day avg -42%
vs 50-day avg -48%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BIOA
this stock
BioAge Labs, Inc.
|
$444.74M | -26.8% | — | — | 5.6% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.85B | +16.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$50.24B | +1.7% | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.41B | -2.4% | — | — | 0.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BIOA | -7.1% | -55.8% | -56.5% | +7.2% | -26.8% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | -5.1% | -59.1% | -67.7% | +5.1% | -38.6% |
Key facts
CIK
1709941
CUSIP
09077V100
13F (30d)
144 filings
142 filers
Visit website
Investor relations